However, most of the previously published reports have elucidated that single therapeutic modality, including those mediated by TRAIL or IL-12 alone, could not pursue in the future to achieve sufficient antitumor responses and thus utilization of combination of anti-anticancer tools, such as those mediated by dual gene-based cancer therapy, holds the great promise for the future of cancer eradication [13, 14, 19, 23, 27, 35]. Here, TNFSF10 is linked to cancer.